Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan-Reference-Cited by-同舟云学术

Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan

Published:2023-09-25 Issue:6 Volume:118 Page:731-736
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Kawashima Ichiro,Hyuga Hideto,Nakadate Ayato,Matsuura Minori,Sakamoto Yuma,Suzuki Jun,Kumagai Takuma,Suzuki Megumi,Koshiishi Megumi,Yamamoto Takeo,Nakajima Kei,Tanaka Masaru,Kirito Keita^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-023-03663-2.pdf

Reference22 articles.

1. Lee LYW, Starkey T, Ionescu MC, Little M, Tilby M, Tripathy AR, et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. Lancet Oncol. 2022;23(6):748–57. https://doi.org/10.1016/S1470-2045(22)00202-9.

2. Pagano L, Salmanton-Garcia J, Marchesi F, Blennow O, Gomes da Silva M, Glenthoj A, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. 2022;140(26):2773–87. https://doi.org/10.1182/blood.2022017257.

3. Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140(3):236–52. https://doi.org/10.1182/blood.2021012251.

4. Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386(23):2188–200. https://doi.org/10.1056/NEJMoa2116620.

5. Kertes J, Shapiro Ben David S, Engel-Zohar N, Rosen K, Hemo B, Kantor A, et al. Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality. Clin Infect Dis. 2023;76(3):126–32. https://doi.org/10.1093/cid/ciac625.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics and COVID-19-related outcomes of immunocompromised patients receiving tixagevimab/cilgavimab pre-exposure prophylaxis in Japan;Journal of Infection and Chemotherapy;2024-07

2. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?;Viruses;2024-02-25